685 related articles for article (PubMed ID: 21609219)
1. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study.
Bashshur ZF; Haddad ZA; Schakal AR; Jaafar RF; Saad A; Noureddin BN
Am J Ophthalmol; 2009 Jul; 148(1):59-65.e1. PubMed ID: 19375689
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study.
Bashshur ZF; Haddad ZA; Schakal A; Jaafar RF; Saab M; Noureddin BN
Am J Ophthalmol; 2008 Feb; 145(2):249-256. PubMed ID: 18067876
[TBL] [Abstract][Full Text] [Related]
6. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
7. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
Algvere PV; Steén B; Seregard S; Kvanta A
Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration.
Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN
Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage.
Stifter E; Michels S; Prager F; Georgopoulos M; Polak K; Hirn C; Schmidt-Erfurth U
Am J Ophthalmol; 2007 Dec; 144(6):886-892. PubMed ID: 17916314
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
12. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
13. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study.
Moshfeghi AA; Rosenfeld PJ; Puliafito CA; Michels S; Marcus EN; Lenchus JD; Venkatraman AS
Ophthalmology; 2006 Nov; 113(11):2002.e1-12. PubMed ID: 17027972
[TBL] [Abstract][Full Text] [Related]
14. [Intravitreal bevacizumab (Avastin) iniections for neovascular age-related macular degeneration (AMD)--preliminary results].
Mackiewicz J; Mańkowska A; Dolar-Szczasny J; Zubilewicz A; Oleszczuk A; Nowomiejska K; Rejdak R; Zagórski Z
Klin Oczna; 2007; 109(4-6):146-9. PubMed ID: 17725273
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study.
Chen CY; Wong TY; Heriot WJ
Am J Ophthalmol; 2007 Mar; 143(3):510-2. PubMed ID: 17317398
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results.
Carneiro AM; Falcão MS; Brandão EM; Falcão-Reis FM
Retina; 2010 Jan; 30(1):85-92. PubMed ID: 20010320
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab for neovascular ocular diseases.
Lynch SS; Cheng CM
Ann Pharmacother; 2007 Apr; 41(4):614-25. PubMed ID: 17355998
[TBL] [Abstract][Full Text] [Related]
18. Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration.
Ladewig MS; Karl SE; Hamelmann V; Helb HM; Scholl HP; Holz FG; Eter N
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):17-25. PubMed ID: 17701197
[TBL] [Abstract][Full Text] [Related]
19. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
